West Pharmaceutical Services (NYSE:WST) Issues Earnings Results

Posted by George Bondi on Oct 29th, 2026

West Pharmaceutical Services (NYSE:WST – Get Free Report) announced its quarterly earnings data on Thursday. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.20 by $0.46, FiscalAI reports. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%. The company had revenue of $874.50 million for the quarter, compared to analyst estimates of $827.12 million. During the same quarter in the previous year, the company earned $1.96 EPS. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year.

Here are the key takeaways from West Pharmaceutical Services’ conference call:

Q3 results exceeded expectations: Revenue rose 8.7% reported and 11.9% organically to $874 million, while adjusted EPS increased 36% to $2.66. Management raised full-year 2026 revenue guidance to $3.41–$3.42 billion and adjusted EPS guidance to $9.38–$9.48.
HVP and GLP-1 demand remained strong. HVP Components grew 20% organically, including GLP-1 growth well into the 30% range and high-teens growth outside GLP-1; the company also added more than 200 HVP upgrade projects this year.
Profitability expanded significantly. Gross margin increased 310 basis points and adjusted operating margin rose 420 basis points year over year, supported by favorable HVP mix, pricing, plant execution and SG&A leverage.
West is investing to support future growth through HVP finishing-capacity expansions in Europe and the U.S., while targeting CapEx of 6%–8% of revenue. New capacity is expected to come online over roughly 18–24 months, with existing facilities expected to support near-term demand.
West Vantage remained in transition, with organic revenue down 6.6% as legacy programs, including a CGM program, rolled off faster than new higher-value programs ramped. In addition, the SmartDose 3.5 divestiture is expected to create an approximately 290-basis-point headwind to reported growth in 2027, while free cash flow was down about 5% year to date due mainly to higher receivables and inventory.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock traded up $16.40 during mid-day trading on Thursday, reaching $420.04. The company had a trading volume of 1,172,613 shares, compared to its average volume of 804,123. West Pharmaceutical Services has a 1 year low of $223.83 and a 1 year high of $438.27. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The company has a market capitalization of $29.56 billion, a P/E ratio of 53.75, a P/E/G ratio of 2.75 and a beta of 1.13. The stock’s 50-day simple moving average is $365.32 and its 200-day simple moving average is $311.80.

West Pharmaceutical Services Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th will be issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.2%. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Tuesday, November 10th. West Pharmaceutical Services’s dividend payout ratio is 13.32%.

Insider Activity

In other news, VP Annette Favorite sold 2,524 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $365.00, for a total transaction of $921,260.00. Following the sale, the vice president owned 21,818 shares of the company’s stock, valued at $7,963,570. The trade was a 10.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 15,659 shares of company stock worth $5,443,749. 0.60% of the stock is currently owned by company insiders.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

Positive Sentiment: Quarterly results exceeded expectations. West reported third-quarter revenue of $874.5 million, up 8.7% year over year and above the $827.1 million consensus estimate. Earnings were $2.66 per share, compared with expectations of approximately $2.18-$2.20 and $1.96 in the prior-year quarter. West Reports Third-Quarter 2026 Results
Positive Sentiment: West raised its 2026 outlook. Full-year revenue guidance increased to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion. Adjusted diluted EPS guidance rose to $9.38-$9.48 from $8.85-$9.05, signaling stronger expected sales, profitability and operating leverage. West Pharmaceutical Services Raises Annual Outlook
Positive Sentiment: High-Value Product Components provided a major growth engine. Sales in this business increased 19.7% and represented 53% of quarterly sales. Management also cited margin expansion, supporting investor confidence in the company’s product mix and demand trends. West Pharma Q3 Earnings Rise on HVP Strength
Neutral Sentiment: Investor positioning is mixed. Several large institutions increased their holdings in the latest quarter, although others reduced exposure. Analysts tracked in the reports have generally been constructive, but the median recent price target of $390 is below the current trading range.
Negative Sentiment: Valuation and insider selling remain risks. A separate analysis argued that West may be overvalued because cash flow has lagged its valuation. In addition, reported insider activity showed sales without purchases over the past six months, potentially limiting enthusiasm after the rally. West Stock Could Be Overvalued

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Citigroup raised their price target on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Zacks Research downgraded West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings raised West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. TD Cowen increased their price objective on West Pharmaceutical Services from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Finally, Morgan Stanley upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $365.00 to $400.00 in a research report on Tuesday, September 22nd. Twelve research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $391.17.

Get Our Latest Report on West Pharmaceutical Services

West Pharmaceutical Services Company Profile

(Get Free Report)

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.